Verseon Corporation (“Verseon” or the “Company”)
Appointment of Corporate Brokers
Fremont, Calif.—Verseon Corporation (AIM:VSN) is pleased to announce the appointment of Cantor Fitzgerald Europe and Mirabaud Securities LLP as its corporate brokers, with immediate effect.
Cenkos Securities acts as the Company’s Nominated Adviser and Broker.
For further information please contact:
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Cenkos Securities (NOMAD and Broker)||+44 (0) 20 7397 8900|
|Mark Connelly / Steve Cox|
|Cantor Fitzgerald Europe (Joint Broker)||+44 (0) 20 7894 7000|
|Marc Milmo / Phil Davies / Callum Butterfield|
|Mirabaud Securities LLP (Joint Broker)||+44 (0) 20 7321 2508|
Financial and business media enquiries:
|Buchanan Communications Ltd (PR Advisors)||+44 (0) 20 7466 5000|
|Henry Harrison-Topham / Sophie Cowles|
Verseon Corporation is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.